Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer
Technology appraisal guidance
Reference number: TA801
Published:
Following an update from the company, NICE will reschedule this appraisal and the committee meeting scheduled for 6 July 2021 will now take place at a later date. This webpage will be updated when the new dates are confirmed.